Drug Profile

APH 0912

Alternative Names: APH-0912

Latest Information Update: 28 Dec 2025

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Aphios Corporation
Class Antineoplastics; Drug conjugates; Immunoconjugates; Monoclonal antibodies; Taxanes
Mechanism of Action Mitosis inhibitors; Tubulin inhibitors; Tubulin polymerisation promoters

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

28 Dec 2025 No recent reports of development identified for preclinical development in Breast-cancer(Metastatic disease) in USA (IV, Infusion)
25 Nov 2021 Preclinical trials in Breast cancer (Metastatic disease) in USA (IV) prior to November 2021 (Aphios Corporation pipeline, November 2021)
25 Nov 2021 Pharmacodynamics data from preclinical studies in cancer released by Aphios Corporation (Aphios Corporation pipeline, November 2021)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com